3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
4
Active not recruiting
2
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
CNS
1
Conditions
Melanoma
7
Colorectal Neoplasms
3
Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Skin Neoplasms
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Neurofibromatosis 1
1
Neoplasm Metastasis
1
Lymphatic Metastasis
1
Lung Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Hematologic Neoplasms
1
Gliosarcoma
1
Glioma
1
Glioblastoma
1
Colonic Neoplasms
1
Brain Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
28
Radiosurgery
19
Radiotherapy
17
Bevacizumab
12
Magnetic Resonance Spectroscopy
9
Radiation
6
Erlotinib Hydrochloride
6
Carboplatin
6
Topotecan
5
Nivolumab
5
Mental Status and Dementia Tests
5
Irinotecan
5
Capecitabine
5
pembrolizumab
4
dabrafenib
4
Trastuzumab
4
Sunitinib
4
Pemetrexed
4
Ipilimumab
4
Filgrastim
4
Cyclophosphamide
4
Aminolevulinic Acid
4
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
4
cabozantinib
3
Vorinostat
3
TPI-287
3
Specimen Handling
3
Radiotherapy, Intensity-Modulated
3
Methylphenidate
3
Lomustine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Brain Neoplasms
×
encorafenib
×
Clear all
NCT03911869
2023-05-31
POLARIS
Pfizer
Phase 2
Terminated
13 enrolled
55 charts